دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
SGLT-2 inhibitors: does it matter if they prevent type 2 diabetes
Alice Y YChenga
Is the impact of add on heart failure therapy influenced by background therapy?
LarsRydénaGiuliaFerranninia
The changing character of diabetes complications
SrikanthBellarya
Opportunities and challenges in closed-loop systems in type 1 diabetes
Leah MWilsonaPeter GJacobsbMichael CRiddellcDessi PZaharievadJessica RCastlea
Telehealth for people with diabetes: poised for a new approach
Korey KHoodaJessie JWonga
Youth-onset type 2 diabetes among First Nations young people in northern Australia: a retrospective, cross-sectional study
AngelaTitmussabdElizabeth ADaviseVickiO'DonnellfMarkWenitonggLouise JMaple-Brownac†AveniHayneseâ€
COVID-19 targets human adrenal glands
WaldemarKanczkowskiaKatjaEverteMarlenaStadtmüllerbMartinaHabereckerfLauraLakshLan-SunChenbKarlFrontzekhJessicaPablikcConstanzeHantelaghFelixBeuschleinghThomasKurthdSvenGruberghAdrianoAguzzihZsuzsannaVargafStefan RBornsteinai
Access to insulin and diabetes care in the Philippines
Michelle Ann BEalaaJohn Jefferson VBesabRegiel Christian QMag-usarabAnna Elvira SArcellanacCecilia AJimenocd
Diabetes and the WHO Model List of Essential Medicines
Farah NKhanaIrl BHirscha
Diabetes and the WHO Model List of Essential Medicines
DavidBeranaStéphaneBesançonbMargaretEwencEdwin A MGaledMariaLazo-PorrasefMollyLepeskacKasiaLipskagJessicaZafra-TanakaefAigerimZhaparovahJohn SYudkini
Diabetes and the WHO Model List of Essential Medicines
DanneabFrancisco JavierAmpudia-BlascocdChantalMathieuef
Diabetes and the WHO Model List of Essential Medicines
RanjitUnnikrishnanabViswanathanMohanab
Diabetes and the WHO Model List of Essential Medicines
AmulyaReddya
Diabetes and the WHO Model List of Essential Medicines
Carissa FEtiennea
COVID-19 and diabetes in Africa: a lethal combination
TalhaBurki
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials
ProfPeterRossingMDabProfSilvio EInzucchicPriyaVartPhDdNielsJongsPhDdKieran FDochertyMBChBePardeep SJhundMBChBeProfLarsKøberMDfProfMikhail NKosiborodMDghProfFelipe AMartinezMDiProfPiotrPonikowskiMDjMarc SSabatineMDklScott DSolomonMDklProfDavid LDeMetsPhDmOlofBengtssonPhLicnMagnusLindbergMScnAnna MariaLangkildeMDnMikaelaSjöstrandMDnBergur VStefanssonMDn…ProfHiddo J LHeerspinkPhDdt
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial
ProfSubodhVermaMDaNitish KDhingraBHScaProfJavedButlerMDbProfStefan DAnkerMDcJoao PedroFerreiraMDdeGerasimosFilippatosMDfJames LJanuzziMDgProfCarolyn S PLamMDhProfNaveedSattarMDiBarbaraPeilDrSc humjMatiasNordabyMDkMartinaBrueckmannMDklProfStuart JPocockPhDmProfFaiezZannadMDdProfMiltonPackerMDno
Trends in leading causes of hospitalisation of adults with diabetes in England from 2003 to 2018: an epidemiological analysis of linked primary care records
JonathanPearson-StuttardFRSPHabYiling JChengPhDgJamesBennettPhDabEszter PVamosFFPHcBinZhouPhDabfProfJonathanValabhjiMDdhiProfAmanda JCrossPhDaeProfMajidEzzatiFMedSciabfjProfEdward WGreggPhDab
Open-source automated insulin delivery: international consensus statement and practical guidance for health-care professionals
KatarinaBrauneMDabc*Rayhan ALalMDd*LenkaPetruželkováMDeGaryScheinerCDCESfPerWinterdijkMDgSigneSchmidtMDhLindaRaimondDSNhProfKorey KHoodPhDdProfMichael CRiddellPhDiProfTimothy CSkinnerPhDjkProfKlemensRaileMDaSufyanHussainPhDlmnOPEN International Healthcare Professional Network and OPEN Legal Advisory Groupâ€
Glycaemic management in diabetes: old and new approaches
ProfAntonioCerielloMDaFrancescoPrattichizzoPhDaProfMoshePhillipMDbcProfIrl BHirschMDdProfChantalMathieuMDeProfTadejBattelinoMDfg
